Impact of SOX18 expression in cancer cells and vessels on the outcome of invasive ductal breast carcinoma

Puła, Bartosz; Olbromski, Mateusz; Wojnar, Andrzej; Gomułkiewicz, Agnieszka; Witkiewicz, Wojciech; Ugorski, Maciej; Dzięgiel, Piotr; Podhorska-Okołów, Marzena

doi:10.1007/s13402-013-0151-7

Cited by 37 publications

(47 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2) (14). The expression of the SOX18 factor in the nuclei of the vascular endothelial cells of the tumor was confirmed, suggesting the participation of SOX18 in the angiogenesis process.…”

Section: Breast Cancermentioning

confidence: 76%

“…Additionally, the level of SOX18 mRNA correlated with the mRNA level of the gene VEGFD, which indicates the role of this protein in the lymphangiogenesis process. Moreover, it was noted that the breast cancer cell lines not expressing the estrogen receptor (ER-), the progesterone receptor (PR-) and the human epidermal growth factor receptor type 2 (HER2-), i.e., the triple negative, were characterized by a negligible expression of SOX18 (14). This may indicate the involvement of this transcription factor in the Wnt/β-catenin pathway, responsible for IDC progression, since similar observations made by other research teams had already indicated the contribution of the SOX18 protein to the regulation of TCF transcription factors (33).…”

Section: Breast Cancermentioning

confidence: 99%

“…This disease is characterized by the simultaneous appearance of abnormalities in hair development, the presence of lymphedema and the widening of small blood vessels. Recent research has also shown its participation in the pathogenesis of many cancers (12)(13)(14)(15). Since different levels of this protein have been observed in different types of tumors, it seems that it can perform various functions in cancer cells (16).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Role of the SOX18 protein in neoplastic processes (Review)

2018

Self Cite

View full text Add to dashboard Cite

Abstract. There is a high demand for anticancer drugs due to the fact that the chemotherapeutics currently used have numerous side effects, which lowers the patient's quality of life. However, the latest antibody therapies are extremely expensive, hence the requirement to identify novel, equally effective but low-toxic treatments that have limited side effects. As a result of this, a number of research centres around the world are attempting to identify novel molecular markers that could be effective targets for anticancer therapy in the future. The SOX18 protein has been suggested to be a significant diagnostic and prognostic marker in various types of cancer. SRY-related HMG-box 18 (SOX18) is an important transcription factor involved in the development of cardiovascular and lymphatic vessels during embryonic development. In addition, it is involved in the progression of atherosclerosis and wound-healing processes. It has been observed that its level is higher in a number of cancer types, including melanoma, pancreas, stomach, liver, breast, lung, ovarian and cervical cancer. Furthermore, an association between a high expression of SOX18 in gastric cancer stromal cells and a poor prognosis has been demonstrated. The literature indicates how complex the pathogenesis of cancer is. Knowing the molecular basis of the pathogenesis of the tumor will allow for the effective use of targeted therapy, which may result in a higher success in treating patients. It is therefore important to identify novel and effective therapies as well as new proteins that could be potential markers. The SOX18 family, represented by the SOX18 protein, seems to be in this respect a promising element in modern anticancer therapy.

show abstract

“…2) (14). The expression of the SOX18 factor in the nuclei of the vascular endothelial cells of the tumor was confirmed, suggesting the participation of SOX18 in the angiogenesis process.…”

Section: Breast Cancermentioning

confidence: 76%

Section: Breast Cancermentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of the SOX18 protein in neoplastic processes (Review)

2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…These data indicated the diagnostic and therapeutic value of SOX18 in osteosarcoma. The involvement of SOX18 in several types of cancer has been an area of investigation, and it has been reported that SOX18 is overexpressed in several types of cancer tissue (10)(11)(12)(13), and that SOX18 may promote cellular proliferation (9,25). Garcia-Ramirez et al (25) found that SOX18 is co-localized with the proliferating cell nuclear antigen protein in vascular smooth muscle cells of human coronary atherosclerotic lesions, and that inhibiting the expression of SOX18 results in a reduced proliferation rate in these cells.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the expression of SOX18 is correlated with poor survival rates (10). The expression of SOX18 has also been correlated with poor clinical outcome in patients with non-small cell lung cancer (11), ovarian cancer (12) and invasive ductal breast carcinoma (13). However, the expression pattern and biological functions of SOX18 in osteosarcoma remain to be fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

SOX18 knockdown suppresses the proliferation and metastasis, and induces the apoptosis of osteosarcoma cells

Liu

Wang

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Sex determining region Y‑box 18 (SOX18) has been found to be overexpressed in several types of tumor. However, the molecular mechanism underlying the biological function of SOX18 in osteosarcoma remains to be elucidated. The present study aimed to elucidate the roles of SOX18 in regulating the biological behavior of osteosarcoma cells. First, SOX18 mRNA expression was analyzed in osteosarcoma tissues using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The results demonstrated that the expression of SOX18 was elevated in osteosarcoma tissue, compared with normal bone tissue. In addition, the knockdown of SOX18 in U2OS or MG63 osteosarcoma cells inhibited cell proliferation and significantly increased the population of cells in the S‑phase of the cell cycle, as measured by the CCK‑8 assay and flow cytometric analysis, respectively. Additionally, suppression of the expression of SOX18 in the osteosarcoma cells significantly induced cell apoptosis as evaluated by annexin V/propidium iodide staining and flow cytometric analysis. The downregulation of SOX18 was found to significantly inhibit cell adhesion and invasion. The mRNA and protein expression levels of transforming growth factor‑β, platelet‑derived growth factor (PDGF)‑A, PDGF‑B and RhoA were also reduced by SOX18 silencing, as assessed by RT‑qPCR and western blot analysis, respectively. These results indicated that SOX18 may function as an oncogene, and may provide a novel and promising therapeutic strategy for osteosarcoma.

show abstract